HALO - ハロザイム・セラピュ―ティクス (Halozyme Therapeutics Inc.) ハロザイム・セラピュ―ティクス

 HALOのチャート


 HALOの企業情報

symbol HALO
会社名 Halozyme Therapeutics Inc (ハロザイム・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ハロザイム・セラピューティクス(Halozyme Therapeutics Inc.)は腫瘍学療法の開発と商業化を行うバイオ医薬品会社である。同社はヒトの酵素および他の候補薬剤の研究、開発、および商業化を行う。同社のセグメントには研究・開発活動およびHylenex組換え品の製品・販売を含む。同社の開発パイプラインは腫瘍学における臨床段階の製品候補を含む。リード腫瘍学プログラムはHAを蓄積する腫瘍の全身治療のために開発された分子実体であるPEGPH20(ポリエチレングリコール(PEG)イル化組換えヒトヒアルロニダーゼ)である。同社はステージIVの膵管腺癌(試験109-202および109-301)におけるPEGPH20の第II相および第III相臨床試験、非小細胞肺癌におけるフェーズIb臨床試験(試験107-201)、および非小細胞肺癌および胃癌におけるフェーズIb臨床試験(試験107-101)にある。   ハロザイム・セラピュ―ティクスは、米国のバイオ医薬品会社。細胞外マトリックスを変更するヒト酵素の研究に基づき、糖尿病、癌、皮膚病治療用の薬品を開発。同社の承認された製品や製品候補は、特許を取得した遺伝子組換え型ヒトヒアルロニダ―ゼ酵素「rHuPH20」をベ―スとしている。主要製品は、「Hylenex」「超高速インスリンプログラム」など。   Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
本社所在地 11388 Sorrento Valley Road San Diego CA 92121 USA
代表者氏名 Connie L. Matsui コニー・マツイ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 858-794-8889
設立年月日 1998年
市場名 NASDAQ National Market System
ipoyear ―年
従業員数 255人
url www.halozyme.com
nasdaq_url https://www.nasdaq.com/symbol/halo
adr_tso
EBITDA EBITDA(百万ドル) 92.39600
終値(lastsale) 17.53
時価総額(marketcap) 2529653327.2
時価総額 時価総額(百万ドル) 2360.817
売上高 売上高(百万ドル) 319.36900
企業価値(EV) 企業価値(EV)(百万ドル) 2127.968
当期純利益 当期純利益(百万ドル) 76.27700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Halozyme Therapeutics Inc. revenues increased 4% to $66.1M. Net loss decreased 21% to $50.4M. Revenues reflect Royalties increase of 43% to $40.9M Revenues under collaborative agreements increase of 33% to $13.9M. Lower net loss reflects Investment and other income increase from $722K to $3.7M (income) Interest expense decrease of 9% to $10M (expense).

 HALOのテクニカル分析


 HALOのニュース

   The Daily Biotech Pulse: Alzheimer's Conference Underway, Biogen's Aducanumab Briefing Doc, Supernus Earnings  2020/11/04 13:21:27 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 3) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) BioLineRx ADR Representing 15 Ord Shs (NASDAQ: BLRX )(reacted to positive readout for its stem cell therapy to treat cancer) Halozyme Therapeutics, Inc. (NASDAQ: HALO )(reacted to its quarterly results) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) ( reported strong results for the third quarter) Immunovant Inc (NASDAQ: IMVT ) Scholar Rock Holding Corp (NASDAQ: SRRK ) Ultragenyx Pharmaceutical Inc (NASDAQ: RARE ) United Therapeutics Corporation (NASDAQ: UTHR ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 3) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aprea Therapeutics Inc (NASDAQ: APRE ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Benitec Biopharma Inc (NASDAQ: BNTC ) Esperion Therapeutics Inc (NASDAQ: ESPR ) (reacted to its quarterly results) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Jaguar Health Inc (NASDAQ: JAGX ) Liminal BioSciences Inc (NASDAQ: LMNL ) Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) Neovasc Inc (NASDAQ: NVCN ) Opthea Spon (NASDAQ: OPT ) Silence Therapeutics ADR (NASDAQ: SLN ) Titan Pharmaceuticals, Inc (NASDAQ: TTNP ) Stocks In Focus Bristol-Myers Squibb Says Antitrust Waiting Period For Proposed Myokardia Acquisition Expires Bristol-Myers Squibb Co (NYSE: BMY ) said the waiting period under the HSR Act in connection with its previously announced tender offer to acquire …
   15 Stocks Moving In Monday's After-Hours Session  2020/11/02 22:18:45 Benzinga
Gainers Arista Networks (NYSE: ANET ) shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also issued Q4 sales guidance below estimates. Halozyme Therapeutics (NASDAQ: HALO ) shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also raised FY20 EPS and sales guidance above estimates. Inspire Medical Systems (NYSE: INSP ) shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. Jazz Pharmaceuticals (NASDAQ: JAZZ ) shares are trading higher after the company reported better-than-expected Q3 EPS and sales results. The company also raised FY20 sales guidance above estimates. Karyopharm Therapeutics (NASDAQ: KPTI ) shares are trading higher after the … Full story available on Benzinga.com
   $0.20 EPS Expected for Halozyme Therapeutics, Inc. (NASDAQ:HALO) This Quarter  2020/10/24 07:08:53 Dispatch Tribunal
Analysts expect that Halozyme Therapeutics, Inc. (NASDAQ:HALO) will announce $0.20 earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have provided estimates for Halozyme Therapeutics’ earnings, with the highest EPS estimate coming in at $0.23 and the lowest estimate coming in at $0.15. Halozyme Therapeutics posted earnings per share of ($0.17) […]
   The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO  2020/10/23 11:26:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Immunomedics, Inc. (NASDAQ: IMMU ) Kodiak Sciences Inc (NASDAQ: KOD ) Nevro Corp (NYSE: NVRO ) Praxis Precision Medicines Inc (NASDAQ: PRAX ) Repligen Corporation (NASDAQ: RGEN ) Replimune Group Inc (NASDAQ: REPL ) (priced its common stock offering of 4.69 million shares at $40 apiece. Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 22) Artelo Biosciences Inc (NASDAQ: ARTL ) Avenue Therapeutics Inc (NASDAQ: ATXI ) Aziyo Biologics Inc (NASDAQ: AZYO ) DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT ) FSD Pharma Inc (NASDAQ: HUGE ) Gilead Sciences, Inc. (NASDAQ: GILD ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) (priced its $15 million worth of common stock offering) Jaguar Health Inc (NASDAQ: JAGX ) Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) Metacrine Inc (NASDAQ: MTCR ) Rockwell Medical Inc (NASDAQ: RMTI ) Satsuma Pharmaceuticals Inc (NASDAQ: STSA ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Stocks In Focus Akebia Presents Positive Phase 3 Data For Anemia Drug In Chronic Kidney Disease Patients Akebia Therapeutics Inc (NASDAQ: AKBA ) presented at the American Society of Nephrology Kidney Week 2020 Reimagined, …
   Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells $365,160.00 in Stock  2020/10/23 08:46:42 Dakota Financial News
Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 12,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $30.43, for a total value of $365,160.00. Following the sale, the senior vice president now owns 146,800 shares of the company’s stock, […]
   Drug Stock May Be Overdue for a Short Squeeze  2020/07/09 18:46:11 Schaeffers Investment Research
Halozyme Therapeutics flashed a bull signal that could push the security to fresh record highs
   Why Is Halozyme Therapeutics (HALO) Up 1% Since Last Earnings Report?  2020/06/10 15:30:46 Zacks Investment Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Will Halozyme Therapeutics Continue to Surge Higher?  2020/05/08 14:34:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor Halozyme Therapeutics
   Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound?  2020/03/25 15:30:24 Zacks Investment Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.
   Drug Stock May Be Overdue for a Short Squeeze  2020/07/09 18:46:11 Schaeffers Investment Research
Halozyme Therapeutics flashed a bull signal that could push the security to fresh record highs
   Why Is Halozyme Therapeutics (HALO) Up 1% Since Last Earnings Report?  2020/06/10 15:30:46 Zacks Investment Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   Will Halozyme Therapeutics Continue to Surge Higher?  2020/05/08 14:34:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor Halozyme Therapeutics
   Halozyme Therapeutics (HALO) Down 20.1% Since Last Earnings Report: Can It Rebound?  2020/03/25 15:30:24 Zacks Investment Research
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection  2020/03/19 11:37:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18) Biomerica, Inc. (NASDAQ: BMRA )( announced commencement of international shipment of rapid COVID-19 test) BioNTech SE – ADR (NASDAQ: BNTX ) Imara Inc (NASDAQ: IMRA ) Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 18) 89bio Inc (NASDAQ: ETNB ) AC Immune SA (NASDAQ: ACIU ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adial Pharmaceuticals Inc (NASDAQ: ADIL ) ADMA Biologics Inc (NASDAQ: ADMA ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Agenus Inc (NASDAQ: AGEN ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Aikido Pharma Inc (NASDAQ: AIKI ) Akorn, Inc. (NASDAQ: AKRX ) Alkermes Plc (NASDAQ: ALKS ) Allogene Therapeutics Inc (NASDAQ: ALLO ) Alterity Therapeutics Ltd (NASDAQ: ATHE ) AMAG Pharmaceuticals, Inc.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ハロザイム・セラピュ―ティクス HALO Halozyme Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)